Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
VUEWAY should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The clinical benefit of VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of VUEWAY (gadopiclenol) at a dose of 0.05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
Avis rectifié en date du 26/11/2024
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
QUBUeqx7AdQ9ExZd
Listen
